Live feed08:00:00·41dPRReleasevia QuantisnowMetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose ControlByQuantisnow·Wall Street's wire, on your screen.MTVA· MetaVia Inc.Health Care
